Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
GAITHERSBURG, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually on September 13-15, 2021.
Details on the H.C. Wainwright fireside chat presentation are as follows:
| Title: | H.C. Wainwright 23rd Annual Global Investment Conference | |||
| Presenters: | Vipin Garg, Ph.D., Chief Executive Officer | |||
| Scott Harris, M.D., Chief Medical Officer | ||||
| Date/Time: | Monday, September 13, 2021 (virtual pre-record available at 7 a.m. EST) |
A webcast link to the fireside chat presentation will be accessible on the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Investor & Media Contacts:
Will Brown
Chief Financial Officer
Phone: 240-654-1450
wbrown@altimmune.com
